Researchers at Moffitt Cancer Center, working with colleagues at The University of Arizona and Arizona State University, have developed a new combination agent approach targeting tumor receptors based on their variety of cell surface proteins. The approach, which was tested in pancreatic cancers and melanoma modeled in tumor-bearing mice, opens the possibility of developing new multivalent agents that can target unique and multiple receptor combinations in tumor cells. This is a significant improvement over current single-target strategies.
Recent PostsSaturday, January 14, 2017
The University of South Florida College of Engineering and the USF Health Morsani College of Medicine have established the Department of Medical Engineering, a unique transdisciplinary concept that will combine the related aspects of engineering and medicine while providing access to real-world health care environments for education and research. ..Read More ⇒Thursday, January 12, 2017
Florida-based Flight Level Engineering has become the first company to join the Customized Business Acceleration Program at the John Mica Engineering and Aerospace Innovation Complex (MicaPlex) at Embry-Riddle Research Park in Daytona Beach. ..Read More ⇒Thursday, January 12, 2017
According to a 2015 report by the NIH’s National Institute on Aging, in the last five years of life, total health care spending for people with dementia was more than a quarter of a million dollars per person, 57 percent more than the costs associated with death from other diseases, including cancer and heart disease. ..Read More ⇒Thursday, January 12, 2017
Immunotherapy is a fast growing area of cancer research. It involves developing therapies that use a patient’s own immune system to fight and kill cancer. Moffitt Cancer Center is working on a new vaccine that would help early-stage breast cancer patients who have HER2 positive disease. ..Read More ⇒Wednesday, January 11, 2017
Graft-versus-host-disease (GVHD) is the leading cause of non-relapse associated death in patients who receive stem cell transplants. In a new study published as the cover story in Science Translational Medicine, Moffitt Cancer Center researchers show that a novel treatment can effectively inhibit the development of GVHD in mice and maintain the infection- and tumor-fighting capabilities of the immune system. ..Read More ⇒
Tagsbiomedical commercialization neuroscience research accolades Moffitt Cancer Center engineering Draper FL Institute for Commercialization of Public Research Florida Power & Light Banyan Biomarkers Florida Atlantic University partnerships aging energy cancer ICFO Univeristy of South Florida nanotechnology Nanotheraputics University of Central Florida Mayo Clinic University of West Florida aerospace photonics Embry-Riddle conference / event Florida International Univ. biochemistry magnets medical agriculture Florida Gulf Coast Univ. accreditation Enterprise Florida children economy business animals marine bioscience environment ecology sustainability society/culture grants IHMC GrowFL University of Miami clean energy AxoGen Max Planck sciences BioFlorida Florida State University awards policy robotics health education Jackson Lab materials science HIV/AIDS green technology astronomy AGTC health care University of North Florida University of Florida Torrey Pines Institute technology stem cell biotechnology Nova Southeastern Univ. research policy innovation Florida Hospital computer science VGTI FAMU Florida Trend consumers Florida Institute of Technology Sanford-Burnham Scripps Research Institute accounting physics gender